Fagron NV (EBR:FAGR)

Market Cap	1.65B +19.6%
Revenue (ttm)	952.17M +9.2%
Net Income	91.02M +13.0%
EPS	1.24 +12.7%
Shares Out	73.35M
PE Ratio	18.15
Forward PE	15.24
Dividend	0.40 (1.78%)
Ex-Dividend Date	May 19, 2025

Volume	222,128
Average Volume	124,670
Open	22.45
Previous Close	22.50
Day's Range	22.40 - 22.80
52-Week Range	18.82 - 23.85
Beta	0.33
RSI	60.45
Earnings Date	Jul 30, 2026

About Fagron NV

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company's products include DiluCap, a line of excipients to compound every capsule formulation; DiluTab, for Cardiology and Primary care application; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for av...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 4,193
• Stock Exchange: Euronext Brussels
• Ticker Symbol: FAGR

Financial Performance

In 2025, Fagron NV's revenue was 952.17 million, an increase of 9.20% compared to the previous year's 871.96 million. Earnings were 91.02 million, an increase of 12.99%.